AIT Therapeutics Announces Publication of Its Phase 2 Trial in Bronchiolitis Patients in the Pediatric Pulmonology Journal

Dec 01, 2017 8:45am EST

AIT Therapeutics Announces Positive Preliminary Data for the Primary Endpoint of Safety in Its NO-NTM Abscessus Phase 2 Clinical Trial in Nontuberculous Mycobacteria (NTM) Patients

Nov 27, 2017 4:56pm EST

AIT Therapeutics to Hold Clinical Update Meeting on November 28, 2017 at 7:30 a.m.

Nov 21, 2017 8:30am EST

AIT Therapeutics Reports Third Quarter 2017 Financial Results

Nov 03, 2017 8:30am EDT

AIT Therapeutics Completes Treatment of Patient Infected with NTM abscessus at the National Institute of Health (NIH) with its Nitric Oxide (NO) Treatment

Nov 02, 2017 8:30am EDT

AIT Therapeutics Enters Letter of Intent to License Revolutionary Nitric Oxide (NO) Delivery System and Adds Two Key Executives with Unparalleled Achievements in Developing NO Delivery Systems

Nov 01, 2017 8:30am EDT

AIT Therapeutics Strengthens Executive Team with Three Key Senior Hires as Company Prepares for Upcoming Clinical Milestones

Oct 26, 2017 8:30am EDT

AIT Therapeutics Announces Third Quarter Financial Results Conference Call/Webcast

Oct 24, 2017 4:30pm EDT

AIT Therapeutics Announces the Last Patient Has Completed Dosing in its Phase 2 NO-NTM Clinical Trial for Patients Suffering from Nontuberculous Mycobacteria (NTM) Abscessus

Oct 23, 2017 8:30am EDT

AIT Therapeutics’ Inhaled Nitric Oxide Therapy Granted Orphan Drug Designation by the U.S. Food and Drug Administration for Treating Infections Caused by Nontuberculous Mycobacteria (NTM)

Oct 03, 2017 8:00am EDT